RxDoctor Payments Data

Cherry Chau, MD

Family Medicine · Houston, TXNPI 1609496462

Payments from drug & device makers

$2,639in general payments, 2019–2025

Across 122 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$632
  • AstraZeneca$468
  • Abbott$387
  • Exact Sciences$251
  • Lilly USA, LLC$233
  • Amgen$167
  • plus $500 from 10 others

What the payments were for

  • Food & beverage$2,639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,639 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$31,803
Medicare patients
95
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$22,364
FarxigaDapagliflozin Propanediol15$13,148
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,257
SynthroidLevothyroxine Sodium11$1,545
Albuterol Sulfate HfaAlbuterol Sulfate30$651
Fluticasone Propionate54$613
Diclofenac Sodium23$452
Atorvastatin Calcium68$438
Gabapentin30$435
Naproxen13$397
Metoprolol Succinate23$393
Rosuvastatin Calcium34$383
Valsartan35$344
Levothyroxine Sodium26$311
Duloxetine Hcl22$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$83$22,36417 claims
AstraZenecaFarxiga$468$13,14815 claims
GSKTrelegy Ellipta$38$7,25711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →